Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026
Voyager Therapeutics presented 6-month GLP toxicology data for VY1706 showing a favorable safety profile and up to 75% reduction in tau protein in key brain regions of non-human primates. The company received FDA IND clearance for VY1706 in June, with dosing in a clinical trial for early Alzheimer's disease expected to begin in the second half of 2026.
Key figures
- Phase Of Trial
- IND cleared (clinical initiation expected H2 2026)
- Target
- MAPT mRNA / tau protein
- Highest dose vg kg
- 5E13
- Study duration months
- 6
- Tau reduction percent
- 75%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.